OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $2.09 per share for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2019-08-09
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2018-03-31 was $3.57, a 14.39% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2017-03-31 was $4.17, a 20.72% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2016-03-31 was $5.26, a 156.59% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2015-03-31 was $2.05.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2018 was $0.76, a 80.61% decline from fiscal 2017.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2017 was $3.92, a 16.77% decline from fiscal 2016.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2016 was $4.71.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2019-06-30 | $2.09 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $1.82 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $0.76 10-K · filed 2019-03-22 | ||||
| 2018-09-30 | $3.25 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $3.35 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $3.57 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $3.92 10-K · filed 2018-03-15 | ||||
| 2017-09-30 | $3.96 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $4.11 10-Q · filed 2017-08-10 | ||||
| 2017-03-31 | $4.17 10-Q · filed 2017-05-11 | ||||
| 2016-12-31 | $4.71 10-K · filed 2017-03-16 | ||||
| 2016-09-30 | $4.96 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $5.34 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | $5.26 10-Q · filed 2016-05-12 | ||||
| 2015-09-30 | $3.67 10-Q · filed 2015-11-12 | ||||
| 2015-06-30 | $3.37 10-Q · filed 2015-08-12 | ||||
| 2015-03-31 | $2.05 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |